BioSpace News Archive

Nine Square Therapeutics announced that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research.

SYNAPS Dx recently participated at BRAINWeek 2023 with the release of compelling data on the performance of the Morphometric Imaging assay of the DISCERN test and the results of a clinical utility study demonstrating the role of DISCERN in informed physician decision-making.

AlgoTherapeutix announces it has dosed the first patients of up to 14, in the US and European centers of its phase II proof of concept trial, called EASE*.

HUTCHMED Limited announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor exon 14 skipping alteration non-small cell lung cancer, were presented during the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, which took place from September 9 to 12, 2023 in Singapore.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has been submitted for peer review publication.

Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce another expansion of novel psychoactive substance testing for its clients.

The newly renamed Montefiore Einstein Comprehensive Cancer Center has been awarded comprehensive designation by the National Cancer Institute of the National Institutes of Health, the ultimate standard achieved by only 55 other NCI cancer centers in the U.S. Through NCI’s peer-review process, MECCC was nationally recognized for its paradigm-shifting, practice-changing, policy-impacting cancer-focused science.

A breakthrough study presented today at the annual meeting of the Congress of Neurological Surgeons found that a combination of remote cognitive behavioral therapy with in-home virtual reality sessions, Vx® Therapy, is effective in reducing pain and behavioral health conditions in patients with chronic cervical and lumbar pain.

4D Molecular Therapeutics, a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York.